Crafting a scientific story that resonates is essential for translating discovery into conviction and capital
For an early-stage rare disease biotech company, the difference between getting funded and being overlooked by investors is rarely the science. It’s whether the science can be quickly understood, trusted, and believed in.
Rare disease companies often house elegant, breakthrough biology. Novel targets. First-in-class mechanisms. Platform-level potential. Deep founder expertise. And yet, many of these companies struggle to convert that scientific strength into investor conviction.
If you’re a scientific founder, the question is not whether your science is strong. It’s whether your story allows others to recognize that strength clearly enough to believe in the research. And if you’re an investor, the question is not just what the data say today. It’s also whether the story gives you confidence in where it can go next.
In a category defined by small patient populations, limited precedent, and high perceived risk, clarity is an essential form of de-risking. Clarity is not simplification. It’s strategy.
At CG Life, where we work at the intersection of rare disease, precision medicine, and early-stage innovation, we see this pattern repeatedly. We observe founders who can explain their work brilliantly to peers in a lab or even a clinical setting, but their stories don’t fully land with other stakeholders, including investors, partners, or broader business audiences who might not typically have a STEM background.
So, let’s change that.
Translating Scientific Risk into Investable Conviction
Let’s start with reframing. This is not about “doing communications” or “dumbing down the science.” We are translating scientific risk into investable conviction.
Venture investors in rare disease are not just evaluating your data. They are evaluating whether your mechanism makes sense, your hypothesis is durable, your approach has a credible path to clinical impact, and who else is trying to do the same thing faster than you.
And, most importantly, whether they can explain your story to their partners in a Monday morning meeting. If they can’t do that clearly, quickly, and confidently, the opportunity will predictably stall.
In rare diseases, especially where datasets are often early-stage and patient populations are extremely small, the stories carry disproportionate weight. Not as PR spin, but as structure.
Confusing Complexity with Credibility
One of the most persistent issues we see is the assumption that hyper-complexity signals more rigor. Think dense slides, layered pathways, and acronyms stacked on acronyms. While you imagine that, also picture investors with glazed eyes, wondering when they can flee to their next meeting.
The reality is that complexity is not a proxy for credibility. If your mechanism-of-action (MoA) slide requires a PhD in a specific subfield to interpret, your investor pool shrank. But you cannot and should not simply “dumb down” the science. You need to prioritize what matters.
The best scientific founders and the most effective scientific storytellers do not remove complexity. They sequence it. They guide the audience through the specific details of their research until they understand it in the context of their field of expertise and life experience.
A Five-Step Framework for Crafting a Scientific Story That Lands
The term “storytelling” is thrown around a lot these days, but what does it actually mean to create a good story? The science may be complex, but the story cannot be.
Here is a practical framework we use with early-stage rare disease companies to build narratives that resonate with scientific and investor audiences.
- The Unmet Need: Most investor decks start here, but few get it right. “High unmet need” alone is not a story. It’s expected. Instead, you need to articulate what exactly is broken in the current standard of care. You need to identify where existing therapies fail in efficacy, durability, safety, and accessibility. You need to highlight the lived clinical reality for patients and physicians. Specificity matters, especially in rare diseases. Investors want to understand not just that a need exists, but why it persists and why no one else is doing anything about it.
- The Biological Insight: This is where your story begins to differentiate itself from the competitors. Explain the “why now”. Illustrate your novel understanding of the disease biology and why your approach is feasible. Create a sense of inevitability, as if a range of things have led to this moment. Not hype or certainty. But, rather, a clear logic that, given what we now know, signals why this approach makes sense.
- The MoA: The most misunderstood and most critical part of the story is the MoA. Yes, it’s science. It’s also the intellectual property that an investor is funding. If an investor cannot explain the MoA to a colleague in 30 seconds, then the narrative is not working. Focus on demonstrating what the therapy does (in plain terms) with clarity and conciseness. Where does it intervene in the disease pathway, and why? What is the expected downstream effect? Of course, you should have deeper scientific layers at the ready, but the core narrative must be intelligible at first pass.
- The Evidence: Early-stage companies often feel constrained here. “We don’t have human data yet.” But evidence extends beyond clinical readouts. Build confidence before clinical data by constructing a trail of credible breadcrumbs: preclinical data signals, translational relevance, analogous successes (same pathway, modality, or target class), and then founder and team expertise as a proxy for credibility. The narrative becomes a tool for risk mitigation.
- The Future State: Without overpromising, describe what success looks like. What changes for patients clinically? What does this validate scientifically? What does this IP unlock strategically? In rare diseases, especially, it’s critical to strike a balance between potential and credibility. Talk about meaningful, measurable impact and improved outcomes.
Use the Framework to Build a Winning Pitch Deck
Now that you’ve created your scientific story to reach and influence potential investors, you might notice that this structure can be used in any medium. Website copy? Yes. A video overview of the company? Definitely. And wouldn’t an improved investor deck be useful? It sure would, so use the following structure to build the five (and only five!) slides that will land the story.
- The Problem Slide: Not prevalence—precision of unmet need
- The Biology Slide: Your “why now” in one clear visual
- The Mechanism Slide: The single most important slide (and usually the one that gets overcomplicated)
- The Evidence Slide: Your de-risking narrative in motion
- The Vision Slide: Where this goes if it works
If these five are clear, aligned, and compelling, the rest of the deck has a chance. If they are not, no amount of additional data will compensate.
Tell the Story Before the Data Inflection
One of the biggest missed opportunities in early-stage rare disease biotech is waiting too long to tell the story. There is a belief that companies should not communicate until they have data. I’ve never understood this logic. The most effective companies build their narrative before the data inflection. They raise awareness and build understanding to establish a following, so the data lands into a ready audience with an existing belief system.
Your core narrative should not just live in your pitch deck. You must translate it into repeatable content. Repurpose and extend it to short-form founder posts on LinkedIn. Create simplified mechanism visuals and 60-second explainers of the science. The pervasiveness of communications is your advantage. That consistency builds familiarity, and familiarity builds trust.
Scientific founders are often underutilized as communicators. And yet, investors consistently say they invest in people before they invest in platforms. That’s why founders should share their perspective on the science and explain the “why” behind the company from the get-go. They must be ready to engage in the broader rare disease conversation and reflect on what it means to them personally. In these interactions, authenticity matters more than polish.
I’ve been earning media for a living for decades, so I say this as bedrock truth: earned media is a means of building validation, credibility, and reputation. However, you can undo that in a second if you use it for promotion. And, in rare disease, credibility matters more than most things. Strategically earned media can validate your scientific approach, position your team as thought leaders, and reinforce your narrative through third parties. But you must rely upon shared insights and perspective, not just press releases.
Remember that Rare Disease Storytelling Is Different
Rare disease biopharma is not just a segment of biotech. It is a fundamentally different storytelling environment in which the story must orient, educate, de-risk, and inspire belief, often before clinical data can do the heavy lifting. Here are just a few of the variables to consider:
- Limited Precedent: There may be no approved therapies, or only one imperfect standard of care. That means fewer comparable therapies and less pattern recognition for investors.
- Small, Heterogeneous Populations: Even within a defined rare disease, patient variability can complicate both the clinical narrative and the commercial case.
- High Emotional Gravity: Patient stories are powerful, but overreliance on them without scientific grounding can undermine credibility with investors.
- Regulatory and Scientific Uncertainty: Accelerated pathways, surrogate endpoints, and evolving FDA expectations create both opportunity and ambiguity.
- Platform vs. Program Tension: Many rare disease companies are platform-driven, but early investors often want a clear, focused program story.
Clarity as a Competitive Advantage
Rare disease biopharma will only become more competitive. In that crowded environment, the companies that win early attention and early capital will not necessarily be the ones with the most complex science. They will be the ones who can clearly explain their science, credibly frame the risk, and build belief before the data fully arrive.
Every molecule, program, and dataset represents not just a market opportunity but a patient population waiting for progress, answers, and, most importantly, solutions. The ability to communicate science effectively is not just a fundraising tool. It could save lives.
